Carcinoidd tumours were first described in 1888 by Lubarsch, who found multiple tumours inn the distal ileum of two patients at autopsy. 1 The term "karzinoide tumoren" was first usedd in 1907 by Oberndorfer to describe a similar tumour which was morphologically distinctt and less aggressive in behaviour than classical adenocarcinomas. Carcinoid tumourss are neuroendocrine tumours derived from enterochromaffin or Kulchitsky cells whichh are widely distributed in the body. For this reason they may be found at any locationn in the body, but they are traditionally described as originating from the foregut, midgutt and hindgut. Thee annual incidence rate of carcinoid is around 2 cases per 100,000 inhabitants and variess with gender, age and race. However, in autopsies the incidental finding of these tumourss is much higher (up to 0.5-1%) with the main location in the small intestine. ' Carcinoidss appear to have an increased overall incidence in the past decades " , possibly ass a result of changes in detection rate. 9 In the age-specific incidence rates a peak between 15-255 years and another between 65-75 years can be found. Under the age of 50 years the incidencee is approximately twice as high in females compared with men. At higher ages a malee predominance is observed with a doubled rate for men compared to women. ' For alll sites, age-adjusted incidence rates are higher in black males (4.48 cases per 100,000 people). 6 6 Thee sites most often affected in carcinoids are the gastrointestinal tract (about 65%) followedd by the bronchopulmonary tract (about 25%). In about 10% the primary tumour remainss unknown. Presentation with distant metastases is found in 22%, half of those with unknownn primaries. Overalll 5-year survival rate for all carcinoid tumours (regardless of site or stage) is 70-8 QO/ 00 6;8;io As m j gnt b e expected, stage of disease influences the prognosis significantly withh the best 5-year survival in localised disease (93%) and a poor 5-year survival in distantt metastatic disease (20-30%). The best overall 5-year survival rates are observed in patientss with appendiceal and lung carcinoid tumours (95 and 80% respectively) due to a loww rate in invasive growth or metastatic spread. Survivall has improved over the last decades. 6;7;1° In a study of Quaedvlieg et al. 10 
Introductionn and epidemiology:
Carcinoidd tumours were first described in 1888 by Lubarsch, who found multiple tumours inn the distal ileum of two patients at autopsy. 1 The term "karzinoide tumoren" was first usedd in 1907 by Oberndorfer to describe a similar tumour which was morphologically distinctt and less aggressive in behaviour than classical adenocarcinomas. Carcinoid tumourss are neuroendocrine tumours derived from enterochromaffin or Kulchitsky cells whichh are widely distributed in the body. For this reason they may be found at any locationn in the body, but they are traditionally described as originating from the foregut, midgutt and hindgut. Thee annual incidence rate of carcinoid is around 2 cases per 100,000 inhabitants and variess with gender, age and race. However, in autopsies the incidental finding of these tumourss is much higher (up to 0.5-1%) with the main location in the small intestine. ' Carcinoidss appear to have an increased overall incidence in the past decades " , possibly ass a result of changes in detection rate. 9 In the age-specific incidence rates a peak between 15-255 years and another between 65-75 years can be found. Under the age of 50 years the incidencee is approximately twice as high in females compared with men. At higher ages a malee predominance is observed with a doubled rate for men compared to women. ' For alll sites, age-adjusted incidence rates are higher in black males (4.48 cases per 100,000 people). 6 6 Thee sites most often affected in carcinoids are the gastrointestinal tract (about 65%) followedd by the bronchopulmonary tract (about 25%). In about 10% the primary tumour remainss unknown. Presentation with distant metastases is found in 22%, half of those with unknownn primaries. Overalll 5-year survival rate for all carcinoid tumours (regardless of site or stage) is 70-8 QO/ 00 6;8;io As m j gnt b e expected, stage of disease influences the prognosis significantly withh the best 5-year survival in localised disease (93%) and a poor 5-year survival in distantt metastatic disease (20-30%) . The best overall 5-year survival rates are observed in patientss with appendiceal and lung carcinoid tumours (95 and 80% respectively) due to a loww rate in invasive growth or metastatic spread. Survivall has improved over the last decades. 6;7;1° In a study of Quaedvlieg et al. 10 the introductionn of octreotide therapy was suggested to be a factor in the improvement of survivall in patients with metastatic disease.
Hereditaryy predisposition:
Informationn about risk factors in carcinoid tumours is scarce and most carcinoids are assumedd to be sporadic. In a minority of patients with a carcinoid tumour, there is a relationshipp with the multiple endocrine neoplasia type 1 (MEN-1). This is an autosomal, dominantlyy inherited disorder, with the MEN-1 gene localised on chromosome 11 (llql3).. The classical syndrome includes neoplasia of the parathyroid glands, pancreas, anteriorr pituitary and neuroendocrine tumours of the lungs, thymus and stomach (foregut). 11 " 133 A family history of carcinoid tumours is reported in less than 1% of the patientss and some case reports have been published on this subject. 14 " 17 However, the relativee risk of developing a carcinoid tumour in an individual with one affected firstdegreee relative is 3.6 (95% CI 3.3-4.1) and with two affected offspring more than 12 (95% CII 3.2-27.4). ' ' A study performed in familial pulmonary carcinoid tumours not associatedd with MEN-1, did not reveal a specific genetic disorder 20 , although lung carcinoidss are more prone to have deletions on chromosome llq. In sporadic midgut carcinoidss a high frequency in deletions of chromosome 18 is described. 21 These findings mightt indicate different pathways in development for carcinoids from foregut and midgut. 22;23 3 
Histologyy and classification:
Inn the last decades several classification systems for endocrine tumours have been applied. Inn 1980 the WHO classification of endocrine tumours applied the term "carcinoid" to all tumourss of the diffuse neuroendocrine system, excluding islet cell tumours, medullary carcinomaa of the thyroid, paraganglioma, small cell lung cancer and Merkel cell tumours off the skin. Subdivision in carcinoids was made on the basis of various silver and other stainingg techniques. In the following years this classification system was overtaken by the developmentt of more detailed immunohistochemical testing methods and a growing demandd for a classification focused on prognostic histological features. Probably the most usefull classification to predict prognosis of neuroendocrine tumours originating from the gastro-intestinall tract, is the revised classification of neuroendocrine tumours of the lung, pancreass and gut by Capella et al. 24 In this classification tumours are graded as: benign, low-gradee malignant and high-grade malignant. The criteria used in this subdivision are histologicall differentiation, tumour size, angioinvasion, and infiltrative growth. This is combinedd with the primary tumour site and production of hormones. Histologicall features related to prognosis in pulmonary neuroendocrine tumours are describedd in a study of Travis et al. 25 A combination of morphology, mitotic index and necrosiss proved to be useful in the prediction of prognosis.
Ann attempt to improve the prognostic power of the classification system was made by Van Eedenn et al. 26 who investigated whether a combination of both systems resulted in a finetuningg of the prediction of prognosis of midgut tumours and unknown primaries. Subdivisionn of these low-grade tumours appeared to be of less value compared to this subdivisionn in neuroendocrine tumours of the lung. In this thesis the term "carcinoid" was usedd to indicate low-grade neuroendocrine tumours of the foregut, midgut and hindgut.
Pathophysiologyy and serotonin metabolism
Dependingg on their site of origin, carcinoid tumours can have the ability to secrete vasoactivee peptides. Serotonin production is the most prominent, especially in midgut tumours.. However, 5-hydroxytryptophan (5-HTP), bradykinins, tachykinins, histamine, substancee P, ACTH and several other peptides are also reported to be produced by carcinoids. . Underr normal conditions about 99% of dietary tryptophan is metabolised by the oxidative pathwayy into nicotinic acid, and less than 1% is converted into 5-HTP. In carcinoid tumourss a disequilibrium of tryptophan metabolism results in 5-hydroxylation of most of thee tryptophan with the production of large quantities of 5-HTP, serotonin (5-HT) and 5hydroxyindoleaceticc acid (5-HIAA). [27] [28] [29] If there is a deficiency in aromatic amino acid decarboxylasee in carcinoid tumour cells, conversion of 5-HT in serotonin will not occur andd the tumours excrete 5-HT instead of serotonin. 30 Due to this shift a reduction in nicotinicc acid pools can cause pellagra in carcinoid patients. 31 " Urinary 5-HIAA, the breakdownn product of serotonin, is still an important marker for carcinoid tumours. 
Clinicall presentation and complications
Carcinoidd tumours have a relatively slow growing pattern and even in the presence of metastaticc disease patients can survive for several years. Unless secretory products are directlyy secreted in the systemic circulation, systemic signs and symptoms are usually not present.. Paracrine secretion of hormonal products in the intestine can cause diarrhoea. If theree is a release of vasoactive peptides in the systemic circulation (in case of liver metastasess or e.g. bronchus carcinoid tumours) patients often present with the characteristicc symptoms of the carcinoid syndrome, such as diarrhoea, flushing and less frequentlyy wheezing. Overproduction of serotonin seems to cause the complaints of diarrhoea.. 4 ' 35 The correlation between serotonin production and symptoms of flushes is nott convincing and probably other hormones like tachykinins are of importance in the pathogenesiss of this symptom. 36 " 40 The cause of wheezing is less clear. It has been supposedd that the release of histamine and serotonin can play a role in this symptom, but clearr evidence is not found in literature.
Carcinoidd heart disease (CHD) is a late complication and occurs in 20-70% of the patients withh metastatic carcinoid tumours. 41 " 44 In many patients the cause of death is attributed directlyy to the cardiac disease. 45 The pathogenesis of carcinoid heart lesions has not yet beenn fully elucidated, but serotonin plays an important role. This is supported by the findingg of similar valve lesions in patients using appetite-suppressants, such as fenfluraminee or dexfenfluramine, and anti-migraine drugs, such as ergotamin and methysergide,, agents which all act via the serotonin pathway. 46 " 48 Inn several studies urinary 5-HIAA excretion, being indicative for the amount of serotonin production,, was significantly higher in patients with carcinoid heart disease compared withh those without. " 4 ' 4 ' 5 Not only a high serotonin level, but also the duration of exposuree to serotonin is important in the development of CHD. 50 Carcinoidd crisis with severe flushes and diarrhoea leading to dehydration, hypotension and arrhythmias,, along with unconsciousness is a potential life-threatening complication. It mightt be provoked by anaesthetic of invasive procedures and is probably caused by an excessivee release of vasoactive peptides into the circulation. Therefore, it is important that prophylacticc measures (such as continuous intravenous octreotide infusion and extra hydrationn started simultaneously with the intervention) are taken during these procedures too prevent a carcinoid crisis. Inn a substantial number of patients the primary tumour remains unknown despite extensive diagnosticc investigations. However, primary tumours in the small bowel can cause complicationss such as bowel obstruction or fibrosis with shrinkage of the mesentery duringg follow-up. Due to mesenterial fibrosis patients can suffer from disabling abdominal painn with malnutrition and kinking of the bowel. Additionally, fibrosis can lead to intestinall ischaemia with finally necrosis and perforation of the bowel wall. 51 " 54 Metastasess to the skin seem to be a late manifestation of advanced disease, but data in the literaturee are scant and limited to single case reports only. 55 " 58 These metastases may presentt as painless subcutaneous nodules 55 , but sometimes they are extremely painful. 58 ' 59 Thee pathogenesis of the severe pain encountered in these often tiny metastatic deposits remainss difficult, as neural involvement is not a consistent finding. Pain can be difficult to managee with analgesics, but local excision demonstrated to provide satisfactory long-term palliation. 59 9 Thee incidence of skeletal metastases in neuroendocrine tumours has been reported to be approximatelyy 10%. 60 " 62 Although bone metastases arise more often from bronchial or hindgutt primaries compared to midgut carcinoid tumours 63;64 , recent studies show no preferentiall primary site. 61;62 The axial skeleton is the most commonly affected site. 6l;65;66 Bonee scintigraphy is the most sensitive nuclear imaging technique to detect bone metastasess in carcinoid disease compared to n, In-pentetreotide and ' 'i-metaiodobenzylguanidinee (MIBG) scintigraphy. 61 ' 62 Pain is the main symptom of bone metastasess and radiotherapy provides satisfactory long-term palliation in majority of patients. .
Diagnosis s
Pathology: Pathology: Inn most patients the diagnosis is based on tissue examination, mostly a biopsy from a liver metastasis.. However, in some patients attempts to collect histologic material can fail and inn these cases diagnosis can be based on symptoms combined with radiologic and scintigraphicc findings. The biopsy material should be examined by a pathologist familiar withh the diagnosis carcinoid to prevent confusion with an adenocarcinoma with neuroendocrinee markers. Depending on the presence of necrosis and/or mitosis, tumours cann be graded as: low-grade malignant and high-grade malignant, which is useful in the predictionprediction of prognosis.
TumourTumour markers:
Urinaryy 5-HIAA, the breakdown product of serotonin, has been the golden standard for diagnosiss and follow-up of carcinoid patients for many years. The specificity of this determinationn is almost 100%, but the sensitivity is reported to be much lower (35%). 67 Urinaryy 5-HIAA levels can be influenced by food (e.g. bananas, avocados, pineapple and walnuts)) and medication. 68;69 Platelett serotonin level is a more sensitive marker for the detection of small amounts of serotonin.. However, in cases with a high rate of serotonin excretion, serotonin in platelets reachh a maximum and can no longer be used for a quantitative determination and hence evaluationn during follow-up. 7071 Chromograninn A (CgA) is an acidic, hydrophilic protein of 49 kDa present in the chromaffinn granules of neuroendocrine cells. In contrast to urinary 5-HIAA levels and platelett serotonin it can be used in the detection of functioning as well as non-functioning tumours.. Although specificity is lower compared to urinary 5-HIAA levels (86 and 100% respectively),, the sensitivity is much higher (35 and 68% respectively). 67 and reported to bee the highest in foregut and functioning tumours. 72 Levels of CgA are correlated to tumourr burden 72 ' 73 and a direct comparison between serum CgA and urinary 5-HIAA levelss showed a higher accuracy of CgA for the detection of a relapse in carcinoid patients.. A significantly worse survival is described in patients with very high levels of CgAA (> 5000 ug/L). 75 Data concerning the value of CgA in the follow-up of carcinoid patientss to monitor treatment effects is scarce and limited to small series. 727677
NuclearNuclear scintigraphy: 1 ''' In-pentetreotide scintigraphy (Octreoscan®):
Somatostatinn receptors (SSR) are located on the cell membrane of carcinoid tumours (especiallyy subtype 2 and 5). Octreotide analogues have a high affinity for the SSR 2 and 55 and a much lower binding to the SSR 1, 3 and 4. 78 ni In-pentetreotide (a radioactive labelledd octreotide analogue) shares the receptor-binding profile of octreotide, which makess it a good radiopharmaceutical for the imaging of carcinoid tumours. 79 The sensitivityy of this scintigraphy has been reported to be 80-90%. 80;8i Apart from informationn about the localisation of the tumour, a positive octreoscan also predicts responsee to octreotide therapy. 82 
I-meta-iodobenzylguanidinee (MIBG) scintigraphy (MIBG-scan):
I-MIBGG is an analogue of a biogenic amine precursor and is taken up by chromaffin cellss and stored in the neurosecretory granules. Using 131 I-MIBG for the detection and imagingg of neuroendocrine tumours was reported in the 80's 83 followed by papers about therapeuticc applications of ' 31 I-MIBG. 84 " 86 The sensitivity of the MIBG-scan is reported to bee a little lower compared to the octreoscan (70 vs. 85%). 81 However, a direct comparison betweenn these two modalities showed comparable results with a sensitivity of about 84%. 80 ,877 A combination of these scans increases the sensitivity to 95%. 80 Bonee scintigraphy: Althoughh ni In-pentetreotide scintigraphy and the 131 I-MIBG scintigraphy are positive in 70-80%% in carcinoid tumours, in the detection of bone metastases these scans are only positivee in 50% and 20% respectively. 61 Bone scintigraphy has a high sensitivity for the detectionn of these metastases of 90-100% and can be used in patients with the suspicion of bonee metastases. 61;62 Positronn emission tomography (PET): PETT scanning using [18F]fluoro-deoxy-glucose (FDG) is widely used as a powerful imagingg technique in clinical oncology. Unfortunately, increased FDG uptake in carcinoid tumourss is limited due to the low proliferative activity and high differentiation. Therefore, severall tracers directed towards the specific characteristics of carcinoid tumours like 6-[18F]fluorodopaminee (18F dopa) and 5-hydroxy-L-tryptophan (5-HTP) were developed forr PET imaging in these tumours. 88 * 9 Although the availability of PET scanning for the clinicall diagnosis of carcinoid tumours is still limited, promising results have been describedd in diagnosing small lesions and lymph node metastases with a sensitivity of up too 65% for the 18F dopa PET. 90 Apartt from the role in staging of carcinoid tumours, uptake of 5-HTP as a tracer in PET scanningg is also of value in follow-up and therapy monitoring. 91
Radiography: Radiography:
Computerisedd tomography scan (CT-scan) can be used for visualizing liver metastases, extraa hepatic tumour localisation in the abdomen (lymph nodes, mesenterial tumour deposition)) and localisation in mediastinum and lungs. In addition to follow-up, the findingss on CT-scan can also be applied for decision making of local treatment options likee resection of metastases in the liver and mesenterium or radiofrequency ablation of liverr metastases. Primaryy tumours in the small bowel can be demonstrated with barium follow-through althoughh small primaries are easily missed by this technique.
VideoVideo capsule endoscopy:
Videoo capsule endoscopy is a new promising technique for the visualization of the mucosa off the small bowel. 92 The first reports on application in patients with small bowel bleeding aree promising and results are better compared to push endoscopy. 93;94 In the diagnosis of Crohn'ss disease this technique seems to be superior to barium follow-through and CTscan. 955966 Experience with the application of the video capsule in carcinoid patients is limited,, but the detection of primary carcinoid tumours in the small bowel and early resectionn is a potential indication for this technique.
CardiacCardiac evaluation:
Detectionn of carcinoid heart disease in an early stage is important to adjust therapy and hencee improve prognosis. Echocardiography in the follow-up and monitoring of carcinoid patientss is the cornerstone for the detection of valvular lesions. However, performing an echocardiographyy is laborious, expensive and not always readily available as referral to a cardiologistt is necessary. A new development is the detection of cardiac damage by using natriureticc peptide (e.g. brain natriuretic peptide, BNP) levels in blood. A regular screeningg of BNP levels might direct the use of cardiac ultrasound and guide treatment strategies. 97 7 
Treatment t

SupportiveSupportive care:
Ass quality of life is severely impaired in patients suffering from the carcinoid syndrome withh flushes and diarrhoea, supportive care in these patients is essential. Flushess can be reduced by avoiding stress and foods known to provoke symptoms (e.g. alcoholicc beverages, spicy meals). Diarrhoea can be treated with simple anti-diarrhoeal medications,, such as loperamide and codeine. Severe diarrhoea can lead to vitamin deficienciess and due to the extensive production of serotonin, a depletion in nicotinic acid cann occur which can cause pellagra. Suppletion of vitamins and nicotinic acid is recommended. .
OctreotideOctreotide analogues:
Somatostatinn interferes with the release of hormones and neurotransmitters through activationn of membrane receptors. It's short half-life (2-4 minutes) limits the clinical application.. Octreotide, a somatostatin analogue, has a half life of 90-120 minutes and can bee administered subcutaneously every 6-8 hours. Octreotide can induce symptomatic improvementt in up to 80% of patients, although a good clinical response is not always reflectedd by a reduction of 5-HIAA excretion in urine, as biochemical response is present inn 70%. 98 " 100 A positive '''In-pentetreotide scintigraphy may be predictive for a clinical responsee to treatment with somatostatin analogues. 82 A major disadvantage is the need for subcutaneouss injections twice (or sometimes thrice) daily. This drawback may be overcomee by slow-release preparations (one intramuscular injection per 2-4 weeks). 10t;102 Inn addition to improvement of symptoms, somatostatin analogues have also been reported too inhibit tumour growth. I00;103;104 However, reduction in tumour volume is only occasionallyy observed.
Interferon-a: Interferon-a:
Interferonn (IFN) has been introduced in 1982 as a treatment modality for carcinoid tumours.. Although IFN is now widely used in the treatment of carcinoid tumours, the exactt mechanism of actions is not yet understood. Possible mechanisms are inhibition of celll proliferation, immune cell mediated cytotoxicity, inhibition of angiogenesis and reductionn in tumour growth by blocking the cell cycle. 106 The biochemical and subjective responsess are reported in respectively 40 and 70% of the patients. 107 ;l08 A reduction in tumourr size is reported in a small minority of patients (about 10-20%) and administration off higher dosages of IFN does not increase this response number. 108 Development of antibodiess during treatment with IFN is described in about 5-20% of the patients and seemss to be higher with the use of interferon-a 2A (Roferon®) compared to interferon-a 2BB (Intron-A®). 109 The role of these antibodies is controversial. Studies in patients with hepatitiss B or C did not reveal a relationship between antibody development and therapeuticc response. u0;111 However, in a study among 327 carcinoid patients high titres off antibodies were associated with a failure of response to treatment, but this phenomenon occurredd late in the disease after a median of 25 months. AA synergism in antiproliferative effects of the combination of octreotide and IFN was reportedd earlier. 112;113 However, in a recent published prospective study of Faiss et al. theree were no differences in response rates by comparing a combination of octreotide and IFNN with either therapy alone. 77 
Meta-iodobenzylguanidineMeta-iodobenzylguanidine (MIBG):
Usingg a tracer dose of 131 I-MIBG for the detection and imaging of neuroendocrine tumourss was reported in the 80's 83 followed by papers about therapeutic applications of a higherr dose 131 I-MIBG. 84 " 86 MIBG is a biogenic amine precursor which resembles noradrenalin.. Due to its high affinity for the noradrenalin transporter protein, it is taken up byy chromaffin cells and stored in neurosecretory granules. 81 Although about 70% of carcinoidd tumours are MIBG-avid, tumour uptake is not always sufficient for therapy. Variouss applications of MIBG can be used in the treatment of carcinoid patients. Apart fromm its help in tumour imaging, successful treatment of carcinoid tumours with I-MIBGG was described in a small series of patients in 1987. 84;85 131 I-MIBG was applied in a muchh higher dose (200 mCI=7.4 GBq) to provide a selective local effect by internal radiationn in the tumour cells in patients with a positive l31 I-MIBG scan. Significant symptomaticc responses were reported in 60% of the patients with a duration of 8 months inn a prospective study of Taal et al. 115 The main disadvantage of this treatment is the need forr isolation as legally required. Application of unlabelled MIBG was reported in 1996; in carcinoidd patients it resulted in symptomatic responses in 60% of the patients with a short mediann duration of 4-5 months. 115 The cytotoxic effect of unlabelled MIBG is related to inhibitionn of mitochondrial respiration and is dependent on anaerobic glycolysis, resulting inn enhanced glucose consumption, increased lactic acid production, inhibition of oxygen consumptionn and decreased adenosine triphosphate levels.
Finally,, the radioactive ("hot") MIBG after predosing with the unlabelled ("cold") MIBG resultedd in improved biodistribution with more intense MIBG uptake in the tumour. In addition,, more patients were eligible for the radioactive treatment after predosing.
RadioactiveRadioactive labelled somatostatin analogues:
Thee somatostatin analogue octreotide has been used since the nineties for imaging and treatmentt of carcinoid tumours. Recently several radioactive labelled somatostatin analoguess have been developed for application in neuroendocrine tumours with a positive In-pentetreotidee scintigraphy, '"in-pentetreotide has a limited radiation range and is suitablee for treatment of small tumours or micrometastases. However, clear tumour reductionn is only reported in a minority of patients while symptomatic improvement is observedd more frequently. 119 " 121 Side-effects are mild and restricted to minor haematologicall toxicity and renal function impairment. 122 Higher tumour radiation can be achievedd by application of 90 Y and 177 Lu which are p-particles with a wider range of radiationn and possibly a higher tumour uptake in neuroendocrine tumour lesions. 123 First reportss of these modalities show a tumour reduction in about 15-30% of the patients with clinicall benefit up to 60%. 124 " 128 Observed toxicities are nausea and vomiting, haematologicall toxicity and some renal function impairment. However, there are some paperss reporting development of end-stage renal failure or myelodysplastic syndrome/leukaemiaa after application of radioactive labelled somatostatin analogues. 129;130 SystemicSystemic chemotherapy: Thee indication for chemotherapy in neuroendocrine tumours is limited and it is reserved forr the high-grade malignancies, which represent only a small minority in this tumour group.. Single-agent chemotherapy is not very useful in the treatment of carcinoid tumours duee to the very low response rates of about 5-10%. 131 Although schedules with a combinationn of chemotherapy have a slight better response rate (15-30%), these results are stilll disappointing. 132 " 135 A direct comparison between IFN and chemotherapy did not resultt in a better response with the application of chemotherapy. 136;137 Therefore, chemotherapyy is not considered to be the first line of treatment in carcinoid tumours.
HepaticHepatic artery (chemo) embolisation (HA(C)E):
Locall treatment of hepatic metastases of carcinoid is attractive because of the slow and localisedd growth pattern. Liver metastases are usually diffuse at the time of diagnosis, and surgicall resection is rarely feasible. Hepatic artery embolisation (HAE) is a local treatment modalityy of the liver, which not only may ameliorate symptoms but also might reduce tumourr burden. An objective or biochemical response up to 50% and a median duration of effectt of 12 months have been reported in cases of failing systemic therapy. 138;139 Reports onn chemoembolisation show a slightly better biochemical and tumour response. 140;141 Side-effectss are pain in the liver region, renal toxicity and elevation of liver enzymes with feverr (post-embolisation syndrome).
0
RadiofrequencyRadiofrequency ablation (RFA): Radiofrequencyy ablation (RFA) is a fairly new technique which can be used in case of noduless up to 4 cm diameter in the treatment of unresectable primary and secondary hepaticc tumours. 142 ' 144 The complication rate is 5-10% and the mortality rate is low with a reductionn in complications with increasing experience with this technique. 145;146 Applicationn of RFA in metastases of neuroendocrine tumours has been reported in small series.. Local tumour control is reported in almost all patients and a symptomatic and biochemicall response in about 60-80% of the patients. However, local recurrence and developmentt of new metastases is frequently reported. 147 
" 150
Conclusions: :
Prognosiss of metastatic carcinoid tumours has improved during the last decade. Due to a longerr survival, complications such as carcinoid heart disease and new metastatic patterns likee skin and bone metastases may become a more important feature in carcinoid disease. Follow-upp should be focused on monitoring tumour size and extension of metastases by CT-scann and nuclear scanning. Special attention should be given on unexpected metastatic patternss like bone metastases. As survival is poor in patients with carcinoid heart disease treatmentt should be focused on reducing elevated levels of hormonal excretion even if theree are no symptoms of the carcinoid syndrome. During follow-up hormonal activity has too be monitored on a regular basis. Routine examinations every 6-12 months to detect carcinoidd related heart disease in an early stage is important to adjust therapy and hence improvee prognosis. Combining new diagnostic and treatment modalities in metastatic carcinoidd patients may result in a better quality of life and a longer survival. The increasingg number of therapeutic options and diagnostic procedures requires a multidisciplinaryy approach with a team consisting of an oncologist, surgeon, pathologist, gastroenterologist,, cardiologist, radiologist and nuclear medicine. Decisions should be madee in multidisciplinary meetings focused on "tailor-made" therapy based on patients' specificc conditions.
